VistaGen Therapeutics Inc. [NASDAQ: VTGN] closed the trading session at $0.55 on 06/17/20. The day’s price range saw the stock hit a low of $0.4902, while the highest price level was $0.5611. The stocks have a year to date performance of -20.26 percent and weekly performance of -1.79 percent. The stock has been moved at -45.54 percent over the last six months. The stock has performed 17.27 percent around the most recent 30 days and changed 73.89 percent over the most recent 3-months.
If compared to the average trading volume of 784.95K shares, VTGN reached to a volume of 1165115 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about VistaGen Therapeutics Inc. [VTGN]:
Maxim Group have made an estimate for VistaGen Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 27, 2018. While these analysts kept the previous recommendation, Chardan Capital Markets dropped their target price from $30 to $22. The new note on the price target was released on February 08, 2018, representing the official price target for VistaGen Therapeutics Inc. stock. Previously, the target price had yet another raise to $4, while Maxim Group analysts kept a Buy rating on VTGN stock.
The Average True Range (ATR) for VistaGen Therapeutics Inc. is set at 0.08
VTGN stock trade performance evaluation
VistaGen Therapeutics Inc. [VTGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.79. With this latest performance, VTGN shares gained by 17.27% in over the last four-week period, additionally sinking by -45.54% over the last 6 months – not to mention a drop of -30.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTGN stock in for the last two-week period is set at 58.39, with the RSI for the last a single of trading hit 59.22, and the three-weeks RSI is set at 56.60 for VistaGen Therapeutics Inc. [VTGN]. The present Moving Average for the last 50 days of trading for this stock 0.4480, while it was recorded at 0.5179 for the last single week of trading, and 0.6848 for the last 200 days.
VistaGen Therapeutics Inc. [VTGN]: An insightful look at the core fundamentals
Return on Total Capital for VTGN is now -347.35, given the latest momentum, and Return on Invested Capital for the company is -351.09. Return on Equity for this stock declined to -351.49, with Return on Assets sitting at -194.46. When it comes to the capital structure of this company, VistaGen Therapeutics Inc. [VTGN] has a Total Debt to Total Equity ratio set at 0.94. Additionally, VTGN Total Debt to Total Capital is recorded at 0.93, with Total Debt to Total Assets ending up at 0.48. Long-Term Debt to Equity for the company is recorded at 0.09, with the Long-Term Debt to Total Capital now at 0.09.
Reflecting on the efficiency of the workforce at the company, VistaGen Therapeutics Inc. [VTGN] managed to generate an average of -$2,732,178 per employee.VistaGen Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.50 and a Current Ratio set at 0.50.
Earnings per share (EPS) analysis for VistaGen Therapeutics Inc. [VTGN] stock
With the latest financial reports released by the company, VistaGen Therapeutics Inc. posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.12/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -41.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VTGN.
VistaGen Therapeutics Inc. [VTGN]: Insider Ownership positions
There are presently around $1 million, or 13.20% of VTGN stock, in the hands of institutional investors. The top three institutional holders of VTGN stocks are: VANGUARD GROUP INC with ownership of 1,206,983, which is approximately 0.199% of the company’s market cap and around 10.27% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 251,656 shares of the stock with an approximate value of $0.13 million in VTGN stocks shares; and ADVISOR GROUP HOLDINGS, INC., currently with $87000.0 in VTGN stock with ownership of nearly New of the company’s market capitalization.
Positions in VistaGen Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 9 institutional holders increased their position in VistaGen Therapeutics Inc. [NASDAQ:VTGN] by around 218,517 shares. Additionally, 6 investors decreased positions by around 356,416 shares, while 11 investors held positions by with 1,838,481 shares. The mentioned changes placed institutional holdings at 2,413,414 shares, according to the latest SEC report filing. VTGN stock had 2 new institutional investments in for a total of 171,514 shares, while 3 institutional investors sold positions of 149,398 shares during the same period.